Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 6/20 | 0.74 |
| ▸ | QPCT | Q16769 | 11/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626420 | 1.00 | QPCTL (0.74) | QPCTLQPCTMEN1KMT2A | |
| SCHEMBL10144453 | 1.00 | QPCTL (0.74) | QPCTLQPCTMEN1KMT2A | |
| SCHEMBL10144452 | 0.91 | QPCTL (0.73) | QPCTLQPCT | |
| SCHEMBL3661669 | 0.91 | QPCTL (0.73) | QPCTLQPCT | |
| SCHEMBL3661673 | 0.91 | QPCTL (0.73) | QPCTLQPCT | |
| SCHEMBL10144433 | 0.87 | ALDH1A1 (0.66) | QPCTLQPCTKMT2A | |
| SCHEMBL5061104 | 0.87 | ALDH1A1 (0.66) | QPCTLQPCTKMT2A | |
| SCHEMBL3625811 | 0.87 | ALDH1A1 (0.66) | QPCTLQPCTKMT2A | |
| SCHEMBL14012457 | 0.85 | QPCTL (1.00) | QPCTLQPCT | |
| SCHEMBL3633424 | 0.85 | QPCTL (1.00) | QPCTLQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142515-B1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-26 | — | — | EP | claimed |
| US-8202897-B2 | pharmaceutically acceptable salt, solvate or polymorph for disease therapy | PROBIODRUG AG (DE) | 2012-06-19 | — | — | US | claimed |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | claimed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | claimed |
| EP-2142515-B1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8202897-B2 | pharmaceutically acceptable salt, solvate or polymorph for disease therapy | PROBIODRUG AG (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-2142515-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008128987-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCTL 20/4885QPCT 3/4885MEN1 1135/4885 |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | GLS, GLS2, GLUL | QPCTL 23/4885QPCT 4/4885MEN1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.